3627 results for «686»
3627 results
Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system
10 Oct 2025 – From AICT-AsiaPCR 2025
Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...
Complex femoral access for TAVI in bicuspid aortic stenosis - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
74 year-old male with history of multiple PCI, PAD, Type 2 DM, presented a symptomatic bicuspid aortic stenosis with a preserved LV function.
They implant a myval 26 mm by right femoral artery access with a right radial secondary access, after a predilation (Balloon 20mm). They prepare...
Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case
30 Sep 2025 – From PCR Gulf Valves 2025
A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...
2 year follow-up of the MITRA-FR study: effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation
03 Sep 2019
At the ESC Congress 2019 in Paris, Jean-François Obadia presented the results of the 2 years follow-Up of the MITRA-FR study. Read the report by Nicole Karam.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Author